Guy Ungerechts

3.1k total citations
62 papers, 2.3k citations indexed

About

Guy Ungerechts is a scholar working on Genetics, Oncology and Epidemiology. According to data from OpenAlex, Guy Ungerechts has authored 62 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Genetics, 30 papers in Oncology and 24 papers in Epidemiology. Recurrent topics in Guy Ungerechts's work include Virus-based gene therapy research (51 papers), Virology and Viral Diseases (23 papers) and CAR-T cell therapy research (23 papers). Guy Ungerechts is often cited by papers focused on Virus-based gene therapy research (51 papers), Virology and Viral Diseases (23 papers) and CAR-T cell therapy research (23 papers). Guy Ungerechts collaborates with scholars based in Germany, Canada and United States. Guy Ungerechts's co-authors include Christine E. Engeland, Christof von Kalle, Sascha Bossow, John C. Bell, Christoph Springfeld, Christian Grossardt, Roberto Cattaneo, Marie Frenzke, Dirk M. Nettelbeck and Mathias F. Leber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Guy Ungerechts

61 papers receiving 2.3k citations

Peers

Countries citing papers authored by Guy Ungerechts

Since Specialization

Citations

This map shows the geographic impact of Guy Ungerechts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Ungerechts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Ungerechts more than expected).

Fields of papers citing papers by Guy Ungerechts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Ungerechts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Ungerechts. The network helps show where Guy Ungerechts may publish in the future.

Co-authorship network of co-authors of Guy Ungerechts

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Ungerechts. A scholar is included among the top collaborators of Guy Ungerechts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Ungerechts. Guy Ungerechts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oncolytic viruses as anticancer agents: clinical progress and remaining challenges 2025 ·The Lancet ·Elizabeth Appleton, E. Antonio Chiocca, Guy Ungerechts, Alan Melcher, Richard G. Vile	0
2	611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors 2024 ·Annals of Oncology ·(unknown), Andréas Mackensen, (unknown), Winfried Alsdorf, (unknown), Daniel Heudobler, (unknown), Antonia Busse, Stephan Mielke, Sander Bins, Guy Ungerechts, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, (unknown), Zhong Wei, (unknown), (unknown), Uğur Şahin	7
3	An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Kevin Kim, Anwaar Saeed, Davendra Sohal, Julien Edeline, Jeong Heo, (unknown), (unknown), Guy Ungerechts	2
4	A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors 2023 ·Cell Death and Disease ·(unknown), (unknown), (unknown), (unknown), (unknown), Johannes Doerner, Hubert Zirngibl, Maximilian Ackermann, H. M. Kvasnicka, Kerry Chester, Dirk Jäger, Claudia R. Ball, Guy Ungerechts, Christine E. Engeland	5
5	Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells 2023 ·Pathogens ·Assia L. Angelova, (unknown), Claudia N. Detje, (unknown), (unknown), Jürg P. F. Nüesch, Ulrich Kalinke, Guy Ungerechts, Jean Rommelaere, Laurent Daeffler	4
6	1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study 2023 ·Annals of Oncology ·Dirk Arnold, Eray Goekkurt, Alexander Stein, Uwe M. Martens, (unknown), Guy Ungerechts, Houra Loghmani, Matt Coffey, Richard Trauger, Thomas C. Heineman	5
7	MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer 2021 ·Molecular Therapy — Oncolytics ·(unknown), Mathias F. Leber, Sascha Bossow, Christine E. Engeland, (unknown), Christian Grossardt, Karim Zaoui, John C. Bell, Dirk Jäger, Christof von Kalle, Guy Ungerechts	14
8	Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Stefan A. Koerber, (unknown), Katharina Dendl, Matthias Uhl, Thomas Lindner, Clemens Kratochwil, Manuel Röhrich, Hendrik Rathke, Guy Ungerechts, Sebastian Adeberg, Klaus Herfarth, D. Jaeger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel	39
9	Engineering and combining oncolytic measles virus for cancer therapy 2020 ·Cytokine & Growth Factor Reviews ·Mathias F. Leber, (unknown), (unknown), Russell A. Barkley, (unknown), John C. Bell, Guy Ungerechts	43
10	Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations 2020 ·Journal of General Virology ·Mathias F. Leber, (unknown), (unknown), (unknown), Christine E. Engeland, (unknown), Sascha Bossow, Christoph Springfeld, Christof von Kalle, Dirk Jäger, John C. Bell, Guy Ungerechts	5
11	Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors 2019 ·Frontiers in Oncology ·(unknown), Janina Frisch, Christine E. Engeland, Frederic B. Thalheimer, Jessica Hartmann, Guy Ungerechts, Christian J. Buchholz	40
12	Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors 2018 ·Clinical Cancer Research ·Tobias Speck, (unknown), Rūta Veinalde, Dirk Jaeger, Christof von Kalle, Claudia R. Ball, Guy Ungerechts, Christine E. Engeland	86
13	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy 2018 ·Science Translational Medicine ·Marie‐Claude Bourgeois‐Daigneault, Dominic G. Roy, Amelia S. Aitken, (unknown), Nikolas T. Martin, Oliver Varette, Theresa Falls, (unknown), Adrian Pelin, Brian D. Lichty, David F. Stojdl, Guy Ungerechts, Jean‐Simon Diallo, John C. Bell	233
14	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy 2018 ·EBioMedicine ·(unknown), (unknown), (unknown), Guy Ungerechts, John C. Bell, Carolina S. Ilkow	125
15	Virotherapy Research in Germany: From Engineering to Translation 2017 ·Human Gene Therapy ·Guy Ungerechts, Christine E. Engeland, Christian J. Buchholz, Jürgen Eberle, Henry Fechner, Karsten Geletneky, Per Sonne Holm, Florian Kreppel, Florian Kühnel, Karl S. Lang, Mathias F. Leber, Antonio Marchini, Markus Moehler, Michael D. Mühlebach, Jean Rommelaere, Christoph Springfeld, Ulrich M. Lauer, Dirk M. Nettelbeck	20
16	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol 2017 ·BMC Cancer ·Jacek Hajda, (unknown), Ottheinz Krebs, Meinhard Kieser, Karsten Geletneky, Dirk Jäger, Michael Dahm, Bernard Huber, Tilman Schöning, Oliver Sedlaczek, Albrecht Stenzinger, Niels Halama, Volker Daniel, Barbara Leuchs, Assia L. Angelova, Jean Rommelaere, Christine E. Engeland, Christoph Springfeld, Guy Ungerechts	40
17	Artificial riboswitches for gene expression and replication control of DNA and RNA viruses 2014 ·Proceedings of the National Academy of Sciences ·Patrick Ketzer, Johanna K. Kaufmann, (unknown), Sascha Bossow, Christof von Kalle, Jörg S. Hartig, Guy Ungerechts, Dirk M. Nettelbeck	90
18	CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy 2014 ·Molecular Therapy ·Christine E. Engeland, Christian Grossardt, Rūta Veinalde, Sascha Bossow, (unknown), Johanna K. Kaufmann, Ivan Shevchenko, Viktor Umansky, Dirk M. Nettelbeck, Wilko Weichert, Dirk Jäger, Christof von Kalle, Guy Ungerechts	239
19	Armed and targeted measles virus for chemovirotherapy of pancreatic cancer 2011 ·Cancer Gene Therapy ·Sascha Bossow, Christian Grossardt, Achim Temme, Mathias F. Leber, Stefan Sawall, E. Peter Rieber, Roberto Cattaneo, Christof von Kalle, Guy Ungerechts	54
20	Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis 2011 ·Molecular Therapy ·Tanner Miest, Koon-Chu Yaiw, Marie Frenzke, Johanna W. Lampe, Andrew W. Hudacek, Christoph Springfeld, Veronika von Messling, Guy Ungerechts, Roberto Cattaneo	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact